Diagnostic utility of impedance-pH monitoring in refractory non-erosive reflux disease

Journal of Neurogastroenterology and Motility

Volumn 20, Issue 4, 2014, Pages 497-505

  Khan, Mohammed Q ^a   Alaraj, Ali ^a   Alsohaibani, Fahad ^a   Al Kahtani, Khalid ^a   Jbarah, Sahar ^a   Al Ashgar, Hamad ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Impedance pH monitoring; Non erosive reflux disease; Refractory NERD

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; BOLUS EXPOSURE TIME; BOLUS INJECTION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ESOPHAGEAL ACID EXPOSURE TIME; EXPOSURE; FEMALE; HEARTBURN; HUMAN; IMPEDANCE; IMPEDANCE PH; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON EROSIVE REFLUX DISEASE; PH; PROSPECTIVE STUDY; SYMPTOM INDEX; TIME;

EID: 84907575612     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm14038     Document Type: Article

References (23)

1. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131-137.
2. Scarpignato C. Poor effectiveness of proton pump inhibitors in nonerosive reflux disease: the truth in the end! Neurogastroenterol Motil 2012;24:697-704.
3. Gupta N, Inadomi JM, Sharma P. Perception about gastroesophageal reflux disease (GERD) and its impact on daily life in the general population: results from a large population based AGA survey. Gastroenterology 2012;142(suppl 1):S411.
4. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664.
5. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophagealimpedance and pH measurement of acid and non-acid reflux: effect of omeprazole. Gastroenterology 2001;120:1599-1606.
6. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-esophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-1031.
7. Savarino E, Zentilin P, Tutuian R, et al. The role of non-acid reflux in NERD-lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103:2685-2693.
8. Johnston BT, Lewis SA, Collins JS, McFarland RJ, Love AH. Acid perception in gastro-oesophageal reflux disease is dependent on psychological factors. Scand J Gastroenterol 1995;30:1-5.
9. Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus 2012;25:682-686.
10. Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009;7:743-748.
11. Tutuian R, Vela MF, Shay SS, Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol 2003;37:206-215.
12. Tutuian R, Mainie I, Agrawal A,Freeman J, Castell DO. Normal values for ambulatory 24-hour combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006;130(suppl 2):A171.
13. Zerbib F, Roman S, Bruley Des Varannes S, et al. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol 2013;11:366-372.
14. Frazzoni M, Savarino E, Manno M, et al. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedancepH monitoring off and on proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;30:508-515.
15. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004;8:890-897.
16. Frazzoni M, Conigliaro R, Mirante VG, Melotti G. The added value of quantitative analysis of on-therapy impedance-pH parameters in distinguishing refractory non-erosive reflux disease from functional heartburn. Neurogastroenterol Motil 2012;24:141-146, e87.
17. Sinn DH, Kim BJ, Son HJ, Kim JJ, Rhee JC, Rhee PL. Pathological bolus exposure may define gastro-esophageal reflux better than pathological acid exposure in patients with globus. Hepatogastroenterology 2012;59:317-320.
18. Kim BJ, Choi SC, Kim JJ, Rhee JC, Rhee PL. Pathological bolusexposure plays a significant role in eliciting non-cardiac chest pain. J Gastroenterol Hepatol 2010;25:1855-1860.
19. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91:1532-1538.
20. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-1402.
21. Zerbib F, Roman S, Ropert A,Chaput U, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-1963.
22. Slaughter JC, Goutte M, Rymer JA, et al. Caution about over interpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011;9:868-874.
23. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005; 54:1067-1071.